Gennao Bio is developing targeted nucleic acid therapeutics to cure muscle diseases. Gene monoclonal antibody (GMAB) technology is an adaptive technology that delivers nucleic acid payloads to select cells through the use of cell penetrating antibodies. Gennao is using their proprietary, non-viral GMAB platform to develop this delivery system. There are several advantages with GMABs: they can be used to deliver a broad range of nucleic acid payloads, they can be targeted selectively to tumor cells and skeletal muscle and they are efficiently uptaken by cells. Gennao is advancing this delivery modality with an initial focus in oncology and rare monogenic skeletal muscle diseases.

Gennao Bio

Founded: 2020
Location: Hopewell, NJ
Employee range: 11 - 50
Funding: $40M A May 2021

Short description:

Drug notes:

Long description:

Jobs: